Targeting tumor micro-environment for design and development ofnovel anti-angiogenic agents arresting tumor growth

Progress in Biophysics and Molecular Biology

Volumn 113, Issue 2, 2013, Pages 333-354

  Gacche, Rajesh N ^a   Meshram, Rohan J ^a  

^a SWAMI RAMANAND TEERTH MARATHWADA UNIVERSITY   (India)

Author keywords

Angiogenesis; Angiogenic cytokines peptides; Antiangiogenic agents

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANGIOGENESIS INHIBITOR; ANGIOGENIC PROTEIN; ANGIOGENIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN RECEPTOR LIKE RECEPTOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 3; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; JANUS KINASE; LINOLENIC ACID; MACROPHAGE INFLAMMATORY PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN; NERVE GROWTH FACTOR; PHORBOL DIBUTYRATE; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROSTAGLANDIN F; RECEPTOR ACTIVITY MODIFYING PROTEIN; SCATTER FACTOR; SOMATOMEDIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

1,3,6-NAPHTHALENETRISULFONATE; 55 KDA PROTEIN; 75 KDA PROTEIN; ALA; AM; AM BINDING PROTEIN-1; AMBP-1; ANDRENOMEDULLIN; ANG; ANGIOGENESIS; ANGIOGENIC CYTOKINES/PEPTIDES; ANGP-1; ANGP-2; ANIMAL; ANTIANGIOGENIC AGENTS; BIOLOGICAL MODEL; CDRS; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLR; CML; COMPLEMENTARITY-DETERMINING REGIONS; CXC RECEPTOR1; CXC RECEPTOR2; CXC RECEPTOR4; CXCR1; CXCR2; CXCR4; CYTOPLASMIC KINASE DOMAIN OF TIE2; DHLA; DIHOMO GAMMA-LINOLENIC ACID; DRUG EFFECT; EC; EGF; EGFR; ENDOTHELIUM CELL; FACTOR-INHIBITING HYPOXIA-INDUCIBLE FACTOR; FGF; FIH; G PROTEIN COUPLED RECEPTORS; HGF; HIF-1; HUMAN; HYPOXIA INDUCIBLE FACTOR-1; IGF; IGF-1R; IGF-2R; IGF-BINDING PROTEINS; IGFBPS; IL-6; IL-6R; IL1R; INSULIN RECEPTORS; INSULIN-LIKE GROWTH FACTOR RECEPTOR TYPE1; INSULIN-LIKE GROWTH FACTOR RECEPTOR TYPE2; IR; JAKS; MCP; METABOLISM; METHODOLOGY; MIP; MOLECULARLY TARGETED THERAPY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NEUROPILIN1; NEUROPILIN2; NGF; NRP 2; NRP1; NTS; P55; P75; PAMP; PATHOLOGY; PGDF; PGDFR; PGFR; PHDS; PHYSIOLOGY; PLACENTA GROWTH FACTOR RECEPTOR; PROADRENOMEDULLIN N-TERMINAL 20 PEPTIDE; PROTEIN DATA BANK; RAMP; REVIEW; RIBONUCLEASE-A; RNASE-A; SCF; SDF-1ALPHA; SDF-1Α; STEM-CELL FACTOR; STROMAL CELL-DERIVED FACTOR-1Α; TGF-Α; TGF-Β; TIE2K; TNF-RECEPTOR; TNF-Α; TNFR; TRANSFORMING GROWTH FACTOR-ALPHA; TRANSFORMING GROWTH FACTOR-BETA; TUMOR MICROENVIRONMENT; TYPE I IL-1 RECEPTOR; VEGF HOMOLOGY DOMAIN; VEGFR; VHD;

1,3,6-NAPHTHALENETRISULFONATE; 55 KDA PROTEIN; 75 KDA PROTEIN; ADENOSINE TRIPHOSPHATE; ALA; ALPHA LINOLENIC ACID; AM; AM BINDING PROTEIN-1; AMBP-1; ANDRENOMEDULLIN; ANG; ANGIOGENESIS; ANGIOGENIC CYTOKINES/PEPTIDES; ANGIOGENIN; ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANGP-1; ANGP-2; ANTIANGIOGENIC AGENTS; ATP; CALCITONIN GENE-RELATED PEPTIDE; CALCITONIN RECEPTOR-LIKE RECEPTOR; CDRS; CGRP; CHRONIC MYELOGENOUS LEUKEMIA; CLR; CML; COMPLEMENTARITY-DETERMINING REGIONS; CXC RECEPTOR1; CXC RECEPTOR2; CXC RECEPTOR4; CXCR1; CXCR2; CXCR4; CYTOPLASMIC KINASE DOMAIN OF TIE2; DHLA; DIHOMO GAMMA-LINOLENIC ACID; EC; EGF; EGFR; ENDOTHELIAL CELLS; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FACTOR-INHIBITING HYPOXIA-INDUCIBLE FACTOR; FGF; FIBROBLAST GROWTH FACTOR; FIH; G PROTEIN COUPLED RECEPTORS; GPCR; HEPATOCYTE GROWTH FACTOR; HGF; HIF-1; HYPOXIA INDUCIBLE FACTOR-1; IGF; IGF-1R; IGF-2R; IGF-BINDING PROTEINS; IGFBPS; IL-1; IL-3; IL-6; IL-6R; IL1R; INSULIN RECEPTORS; INSULIN-LIKE GROWTH FACTOR; INSULIN-LIKE GROWTH FACTOR RECEPTOR TYPE1; INSULIN-LIKE GROWTH FACTOR RECEPTOR TYPE2; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN-1; INTERLEUKIN-3; IR; JAKS; JANUS KINASES; MACROPHAGE INFLAMMATORY PROTEIN; MCP; MIP; MONOCYTE CHEMOTACTIC PROTEIN; NERVE GROWTH FACTOR; NEUROPILIN1; NEUROPILIN2; NGF; NRP 2; NRP1; NTS; P55; P75; PAMP; PDB; PGDF; PGDFR; PGF; PGFR; PHDS; PLACENTA GROWTH FACTOR; PLACENTA GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROADRENOMEDULLIN N-TERMINAL 20 PEPTIDE; PROLYL HYDROXYLASES; PROTEIN DATA BANK; RAMP; RECEPTOR ACTIVITY MODIFYING PROTEIN; RIBONUCLEASE-A; RNASE-A; SCF; SDF-1ALPHA; SDF-1Α; STEM-CELL FACTOR; STROMAL CELL-DERIVED FACTOR-1Α; TGF-Α; TGF-Β; TIE2K; TNF-RECEPTOR; TNF-Α; TNFR; TRANSFORMING GROWTH FACTOR-ALPHA; TRANSFORMING GROWTH FACTOR-BETA; TUMOR NECROSIS FACTOR-ALPHA; TYPE I IL-1 RECEPTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF; VEGF HOMOLOGY DOMAIN; VEGF RECEPTOR; VEGFR; VHD;

ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; ANIMALS; CELL PROLIFERATION; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MICROENVIRONMENT;

EID: 84887609331     PISSN: 00796107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbiomolbio.2013.10.001     Document Type: Review

References (261)

1. Aase K., Lymboussaki A., Kaipainen A., Olofsson B., Alitalo K., Eriksson U. Localization of VEGF-B in the mouse embryo suggests a paracrine role of the growth factor in the developing vasculature. Dev. Dyn. 1999, 215:12-25.
2. Allegretti M., Bertini R., Cesta M.C., Bizzarri C., Di Bitondo R., Di Cioccio V., Galliera E., Berdini V., Topai A., Zampella G., Russo V., Di Bello N., Nano G., Nicolini L., Locati M., Fantucci P., Florio S., Colotta F. 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J.Med. Chem. 2005, 48:4312-4331.
3. Allen J.E., Ferrini R., Dicker D.T., Batzer G., Chen E., Oltean D.I., Lin B., Renshaw M.W., Kretz-Rommel A., El-Deiry W.S. Targeting TRAIL death receptor 4 with trivalent DR4 Atrime complexes. Mol. Cancer Ther. 2012, 11:2087-2095.
4. Appleton B.A., Wu P., Maloney J., Yin J., Liang W.C., Stawicki S., Mortara K., Bowman K.K., Elliott J.M., Desmarais W., Bazan J.F., Bagri A., Tessier-Lavigne M., Koch A.W., Wu Y., Watts R.J., Wiesmann C. Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding. EMBO J. 2007, 26:4902-4912.
5. Arany Z., Huang L.E., Eckner R. An essential role for p300/CBP in the cellular response to hypoxia. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:12969-12973.
6. Arnold L.D., Calderwood D.J., Dixon R.W., Johnston D.N., Kamens J.S., Munschauer R., Rafferty P., Ratnofsky S.E. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I. Bioorg. Med. Chem. Lett. 2000, 10:2167-2170.
7. Bach L.A., Hsieh S., Sakano K., Fujiwara H., Perdue J.F., Rechler M.M. Binding of mutants of human insulin-like growth factor II to insulin-like growth factor binding proteins 1-6. J.Biol. Chem. 1993, 268:9246-9254.
8. Badet J. Angiogenin, a potent mediator of angiogenesis. Biological, biochemical and structural properties. Pathol. Biol. (Paris) 1993, 47:345-351.
9. Baggiolini M., Dewald B., Moser B. Human chemokines: an update. Annu. Rev. Immunol. 1997, 15:675-705.
10. Bajaj M., Waterfield M.D., Schlessinger J., Taylor W.R., Blundell T. On the tertiary structure of the extracellular domains of the epidermal growth factor and insulin receptors. Biochim. Biophys. Acta 1987, 16:220-226.
11. Beerli R.R., Hynes N.E. Epidermal growth factor related peptides activate distinct subsets of ErbB receptors and differ in their biological activities. J.Biol. Chem. 1996, 271:6071-6076.
12. 2+-dependent, agonist-stimulated secretion of human adrenal glands. Hypertension 1999, 33:1185-1189.
13. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. The protein data bank. Nucleic Acids Res. 2000, 28:235-242.
14. Bicknell R., Vallee B.L. Angiogenin stimulates endothelial cell prostacyclin secretion by activation of phospholipase A2. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:1573-1577.
15. Borhani D.W., Calderwood D.J., Friedman M.M., Hirst G.C., Li B., Leung A.K., McRae B., Ratnofsky S., Ritter K., Waegell W. A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection. Bioorg. Med. Chem. Lett. 2004, 14:2613-2616.
16. Bottaro D.P., Rubin J.S., Faletto D.L., Chan A.M., Kmiecik T.E., Vande Woude G.F., Aaronson S.A. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1999, 251:802-804.
17. Brizzi M.F., Formato L., Dentelli P., Rosso A., Pavan M., Garbarino G., Pegoraro M., Camussi G., Pegoraro L. Interleukin-3 stimulates migration and proliferation of vascular smooth muscle cells: a potential role in atherogenesis. Circulation 2001, 103:549-554.
18. Brown J., Esnouf R.M., Jones M.A., Linnell J., Harlos K., Hassan A.B., Jones E.Y. Structure of a functional IGF2R fragment determined from the anomalous scattering of sulfur. EMBO J. 2002, 21:1054-1062.
19. Bruick R.K., McKnight S.L. Aconserved family of prolyl-4-hydroxylases that modify HIF. Science 2001, 294:1337-1340.
20. Buchstein N., Hoffmann D., Smola H., Lang S., Paulsson M., Niemann C., Krieg T., Eming S.A. Alternative proteolytic processing of hepatocyte growth factor during wound repair. Am. J. Pathol. 2009, 174:2116-2128.
21. Byla P., Andersen M.H., Holtet T.L., Jacobsen H., Munch M., Gad H.H., Thøgersen H.C., Hartmann R. Selection of a novel and highly specific tumor necrosis factor-a (TNF-a) antagonist: insight from the crystal structure of the antagonist-TNF-a complex. J.Biol. Chem. 2010, 285:12096-12100.
22. Campbell I.D., Cooke R.M., Baron M., Harvey T.S., Tappin M.J. The solution structures of epidermal growth factor and transforming growth factor alpha. Prog. Growth Factor Res. 1989, 1:13-22.
23. Campion S.R., Matsunami R.K., Engler D.A., Niyogi S.K. Biochemical properties of site-directed mutants of human epidermal growth factor: importance of solvent-exposed hydrophobic residues of the amino-terminal domain in receptor binding. Biochemistry 1990, 29:9988-9993.
24. Canales A., Lozano R., Lopez-Mendez B., Angulo J., Ojeda R., Nieto P.M., Martin-Lomas M., Gimenez-Gallego G., Jimenez-Barbero J. Solution NMR structure of a human FGF-1 monomer, activated by a hexasaccharide heparin-analogue. FEBS. J. 2006, 273:4716-4727.
25. Carpenter G., Cohen S. Epidermal growth factor. J.Biol. Chem. 1990, 265:7709-7712.
26. Carrero P., Okamoto K., Coumailleau P., O'Brien S., Tanaka H., Poellinger L. Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1alpha. Mol. Cell Biol. 2000, 20:402-415.
27. Cases A. The latest advances in kidney diseases and related disorders. Drug News Perspect. 2007, 20:647-654.
28. Chamberlin S.J., Brennan L., Puddicombe S.M., Davies D.E., Turner D.L. Solution structure of the mEGF/TGFa44250 chimeric growth factor. Eur. J. Biochem. 2001, 268:6247-6255.
29. Chan A.M., Rubin J.S., Bottaro D.P., Hirschfield D.W., Chedid M., Aaronson S.A. Identification of a competitive HGF antagonist encoded by an alternative transcript. Science 1991, 254:1382-1385.
30. Christinger H.W., Fuh G., de Vos A.M., Wiesmann C. The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1. J.Biol. Chem. 2004, 279:10382-10388.
31. Clements J.M., Bawden L.J., Bloxidge R.E., Catlin G., Cook A.L., Craig S., Drummond A.H., Edwards R.M., Fallon A., Green D.R. Two PDGF-B chain residues, arginine 27 and isoleucine 30, mediate receptor binding and activation. EMBO J. 1991, 10:4113-4120.
32. Cohen T., Nahari D., Cerem L.W., Neufeld G., Levi B.Z. Interleukin 6 induces the expression of vascular endothelial growth factor. J.Biol. Chem. 1996, 271:736-741.
33. Compagni A., Wilgenbus P., Impagnatiello M.A., Cotton M., Christofori G. Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res. 2000, 60:7163-7169.
34. Dames S.A., Yamout M.M., De Guzman R.N., Dyson H.J., Wrigh P.E. Structural basis for Hif-1alpha/CBP recognition in the cellular hypoxic response. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:5271-5276.
35. D'Andrea L.D., Gatto A.D., Pedone C., Benedetti E. Peptide-based molecules in angiogenesis. Chem. Biol. Drug Des. 2006, 67:115-126.
36. Dealwis C., Fernandez E.J., Thompson D.A., Simon R.J., Siani M.A., Lolis E. Crystal structure of chemically synthesized [N33A] stromal cell-derived factor 1a, a potent ligand for the HIV-1 "fusin" coreceptor. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6941-6946.
37. Delafontaine P., Song Y., Li Y. Expression, regulation and function of IGF-1, IGF-1R and IGF-1 binding proteins in blood vessels. Arterioscler. Thromb. Vasc. Biol. 2004, 24:435-444.
38. Denley A., Cosgrove L.J., Booker G.W., Wallace J.C., Forbes B.E. Molecular interactions of the IGF system. Cytokine Growth Factor Rev. 2005, 16:421-439.
39. Dentelli P., Del Sorbo L., Rosso A., Molinar A., Garbarino G., Camussi G., Pegoraro L., Brizzi M.F. Human IL-3 stimulates endothelial cell motility and promotes invivo new vessel formation. J.Immunol. 1999, 163:2151-2159.
40. Detoraki A., Staiano R.I., Granata F., Giannattasio G., Prevete N., de Paulis A., Ribatti D., Genovese A., Triggiani M., Marone G. Vascular endothelial growth factors synthesized by human lung mast cells exert angiogenic effects. J.Allergy Clin. Immunol. 2009, 123:1142-1149.
41. Dransfield D.T., Cohen E.H., Chang Q. Ahuman monoclonal antibody against insulin-like growth factor-II blocks the growth of human hepatocellular carcinoma cell lines invitro and invivo. Mol. Cancer Ther. 2010, 9:1809-1819.
42. Eder J.P., VandeWoude G.F., Boerner S.A., LoRusso P.M. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin. Cancer Res. 2009, 15:2207-2213.
43. Eilken H.M., Adams R.H. Dynamics of endothelial cell behavior in sprouting angiogenesis. Curr. Opin. Cell. Biol. 2010, 22:617-625.
44. Elkins J.M., Kirsty S., Hewitson K.S., McNeill L.A., Seibel J.F., Schlemminger I., Pugh C.W., Ratcliffe P.J., Schofield C.J. Structure of factor-inhibiting hypoxia-inducible factor (HIF) reveals mechanism of oxidative modification of HIF-1a. J.Biol. Chem. 2003, 278:1802-1806.
45. Elleman T.C., Domagala T., McKern N.M., Nerrie M., Lönnqvist B., Adams T.E., Lewis J., Lovrecz G.O., Hoyne P.A., Richards K.M., Howlett G.J., Rothacker J., Jorissen R.N., Lou M., Garrett T.P., Burgess A.W., Nice E.C., Ward C.W. Identification of a determinant of epidermal growth factor receptor ligand-binding specificity using a truncated, high-affinity form of the ectodomain. Biochemistry 2001, 40:8930-8939.
46. Ellis L. Epidermal growth factor receptor in tumor angiogenesis. Hematol. Oncol. Clin. North. Am. 2004, 18:1007-1021.
47. Ellis L.M. The role of neuropilins in cancer. Mol. Cancer Ther. 2006, 5:1099-1107.
48. Eman R.M., Oner F.C., Kruyt M., Dhert W., Alblas J. Stromal cell-derived factor-1 stimulates cell recruitment, vascularization and osteogenic differentiation. Tissue Eng. A 2013, 10.1089/ten.TEA.2012.0653.
49. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. 2004, 60:2126-2132.
50. Engler D.A., Campion S.R., Hauser M.R., Cook J.S., Niyogi S.K. Critical functional requirement for the guanidinium group of the arginine 41 side chain of human epidermal growth factor as revealed by mutagenic inactivation and chemical reactivation. J.Biol. Chem. 1992, 267:2274-2281.
51. Enholm B., Paavonen K., Ristimaki A., Kumar V., Gunji Y., Klefstrom J., Kivinen L., Laiho M., Olofsson B., Joukov V., Eriksson U., Alitalo K. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene 1997, 14:2475-2483.
52. Epstein R.J. The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies. Nat. Rev. Cancer 2004, 4:901-909.
53. Fan F., Stoeltzing O., Liu W., McCarty M.F., Jung Y.D., Reinmuth N., Ellis L.M. Interleukin-1b regulates Angiopoietin-1 expression in human endothelial cells. Cancer Res. 2004, 64:3186-3190.
54. Fedorova A., Zobel K., Gill H.S., Ogasawara A., Flores J.E., Tinianow J.N., Vanderbilt A.N., Wu P., Meng Y.G., Williams S.P., Wiesmann C., Murray J., Marik J., Deshayes K. The development of peptide-based tools for the analysis of angiogenesis. Chem. Biol. 2011, 18:839-845.
55. Ferguson K.M., Berger M.B., Mendrola J.M., Cho H.S., Leahy D.J., Lemmon M.A. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol. Cell 2003, 11:507-517.
56. Fernández I.S., Cuevas P., Angulo J., López-Navajas P., Canales-Mayordomo A., González-Corrochano R., Lozano R.M., Valverde S., Jiménez-Barbero J., Romero A., Giménez-Gallego G. Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of invivo fibroblast growth factor inhibitors. J.Biol. Chem. 2010, 285:11714-11729.
57. Ferrari G., Cook B.D., Terushkin V., Pintucci G., Mignatti P. Transforming growth factor-beta 1 (TGFbeta1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis. J.Cell. Physiol. 2009, 219:449-458.
58. Fett J.W., Olson K.A., Rybak S.M. Amonoclonal antibody to human angiogenin. Inhibition of ribonucleolytic and angiogenic activities and localization of the antigenic epitope. Biochemistry 1994, 33:5421-5427.
59. Fiedler U., Krissl T., Koidl S., Weiss C., Koblizek T., Deutsch U., Martiny-Baron G., Marme D., Augustin H.G. Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats. J.Biol. Chem. 2003, 278:1721-1727.
60. Fiorillo M.T., Cabibbo A., Iacopetti P., Fattori E., Ciliberto G. Analysis of human/mouse interleukin-6 hybrid proteins: both amino and carboxy termini of human interleukin-6 are required for invitro receptor binding. Eur. J. Immunol. 1992, 22:2609-2615.
61. Fontaine V., Savino R., Arcone R., De Wit L., Brackenhoff J.P.J., Content J., Ciliberto G. Involvement of the Arg179 in the active site of human IL-6. Eur. J. Biochem. 1993, 211:749-755.
62. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., Semenza G.L. Activation of vascular endothelial growth factor gene transcription by hypoxiainducible factor 1. Mol. Cell Biol. 1996, 16:4604-4613.
63. Friedmann E., Hauben E., Maylandt K., Schleeger S., Vreugde S., Lichtenthaler S.F., Kuhn P.H., Stauffer D., Rovelli G., Martoglio B. SPPL2a and SPPL2b promote intramembrane proteolysis of TNFalpha in activated dendritic cells to trigger IL-12 production. Nat. Cell Biol. 2006, 8:843-848.
64. Fuh G., Garcia K.C., de Vos A.M. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. J.Biol. Chem. 2000, 275:26690-26695.
65. Fuh G., Li B., Crowley C., Cunningham B., Wells J.A. Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J.Biol. Chem. 1998, 273:11197-11204.
66. Gacche R.N., Shegokar H.D., Gond S.D., Yang Z., Jadhav A.D. Evaluation of selected flavonoids as antiangiogenic, anticancer, and radical scavenging agents: an experimental and in silico analysis. Cell. Biochem. Biophys. 2011, 61:651-663.
67. Gacche R.N., Shegokar H.D., Gond S.D., Jadhav A.D., Ghole V. Effect of hydroxyl substitution of flavone on angiogenesis and free radical scavenging activities: a structure-activity relationship studies using computational tools. Eur. J. Pharm. Sci. 2010, 39:37-44.
68. Galzie Z., Kinsella A.R., Smith J.A. Fibroblast growth factors and their receptors. Biochem. Cell. Biol. 1997, 75:669-685.
69. Ganser A. Clinical results with recombinant human interleukin-3. Cancer Invest 1993, 11:212-218.
70. Gharaee-Kermani M., Hu B., Thannickal V.J., Phan S.H., Gyetko M.R. Current and emerging drugs for idiopathic pulmonary fibrosis. Expert Opin. Emerg. Drugs 2007, 12:627-646.
71. Gherardi E., Gray J., Stoker M., Perryman M., Furlong R. Purification of scatter factor, a fibroblast-derived basic protein that modulates epithelial interactions and movement. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:5844-5848.
72. Giese N., LaRochelle W.J., May-Siroff M., Robbins K.C., Aaronson S.A. Asmall v-sis/platelet-derived growth factor (PDGF) B-protein domain in which subtle conformational changes abrogate PDGF receptor interaction and transforming activity. Mol. Cell Biol. 1990, 10:5496-5501.
73. Gill A.L., Verdonk M., Boyle R.G., Taylor R. Acomparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr. Top. Med. Chem. 2007, 7:1408-1422.
74. Goel S., Duda D.G., Xu L., Munn L.L., Boucher Y., Fukumura D., Jain R.K. Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 2011, 91(3):1071-1121.
75. Greenberger L.M., Horak I.D., Filpula D., Sapra P., Westergaard M., Frydenlund H.F., Albaek C., Schrøder H., Ørum H. ARNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol. Cancer Ther. 2008, 7:3598-3608.
76. Groenen L.C., Nice E.C., Burgess A.W. Structure-function relationships for the EGF/TGF-family of mitogens. Growth Factors 1994, 11:235-257.
77. Gu C., Limberg B.J., Whitaker G.B., Perman B., Leahy D.J., Rosenbaum J.S., Ginty D.D., Kolodkin A.L. Characterization of neuropilin- 1 structural features that confer binding to semaphorin 3A and vascular endothelial growth factor 165. J.Biol. Chem. 2002, 277:18069-18076.
78. Guo Q., Manolopoulou M., Bian Y., Schilling A.B., Tang W.J. Molecular basis for the recognition and cleavages of IGF-II, TGF-alpha, and amylin by human insulin-degrading enzyme. J.Mol. Biol. 2010, 395:430-443.
79. Hague S., Zhang L., Oehler M.K., Manek S., MacKenzie I.Z., Bicknell R., Rees M.C. Expression of the hypoxically regulated angiogenic factor adrenomedullin correlates with uterine leiomyoma vascular density. Clin. Cancer Res. 2000, 3:2808-2814.
80. Hall J.M., Korach K.S. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol. Endocrinol. 2003, 17:792-803.
81. Hallahan T.W., Shapiro R., Strydom D.J., Vallee B.L. Importance of asparagine-61 and asparagine-109 to the angiogenic activity of human angiogenin. Biochemistry 1992, 31:8022-8029.
82. Hallahan T.W., Shapiro R., Vallee B.L. Dual site model for the organogenic activity of angiogenin. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:2222-2226.
83. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
84. Harpaz Y., Chothia C. Many of the immunoglobulin superfamily domains in cell adhesion molecules and surface receptors belong to a new structural set which is close to that containing variable domains. J.Mol. Biol. 1994, 238:528-539.
85. Hauser S., Weich H.A. Aheparin-binding form of placenta growth factor (PlGF-2) is expressed in human umbilical vein endothelial cells and in placenta. Growth Factors 1993, 9:259-268.
86. Hayek A., Culler F.L., Beattie G.M., Lopez A.D., Cuevas P., Baird A. An invivo model for study of the angiogenic effects of basic fibroblast growth factor. Biochem. Biophys. Res. Commun. 1987, 147:876-880.
87. Hayrabedyan S., Kyurkchiev S., Kehayov I. FGF-1 and S100A13 possibly contribute to angiogenesis in endometriosis. J.Reprod. Immunol. 2005, 67:87-101.
88. Hébert C.A., Vitangcol R.V., Baker J.B. Scanning mutagenesis of IL-8 identifies a cluster of residues required for receptor binding. J.Biol. Chem. 1991, 266:18989-18994.
89. Heinrich P.C., Behrmann I., Muller-Newen G., Schaper F., Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 1998, 334:297-314.
90. Hodous B.L., Geuns-Meyer S.D., Hughes P.E., Albrecht B.K., Bellon S., Bready J., Caenepeel S., Cee V.J., Chaffee S.C., Coxon A., Emery M., Fretland J., Gallant P., Gu Y., Hoffman D., Johnson R.E., Kendall R., Kim J.L., Long A.M., Morrison M., Olivieri P.R., Patel V.F., Polverino A., Rose P., Tempest P., Wang L., Whittington D.A., Zhao H. Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor. J.Med. Chem. 2007, 50:611-626.
91. Hoffmann A., Kovermann M., Lilie H., Fiedler M., Balbach J., Rudolph R., Pfeifer S. New binding mode to TNF-alpha revealed by ubiquitin-based artificial binding protein. PLoS. ONE 2012, 7:e31298.
92. Holloway D.E., Shapiro R., Hares M.C., Leonidas D.D., Acharya K.R. Guest-host crosstalk in an angiogenin-Rnase a chimeric protein. Biochemistry 2002, 41:10482-10489.
93. Holmes W.D., Consler T.G., Dallas W.S., Rocque W.J., Willard D.H. Solution studies of recombinant human stromal-cell-derived factor-1. Protein Expr. Purif. 2001, 21:367-377.
94. Hosokawa N., Yamamoto S., Uehara Y., Hori M., Tsuchiya K.S. Effect of thiazinotrienomycin B, an ansamycin antibiotic, on the function of epidermal growth factor receptor in human stomach tumor cells. J.Antibiot. (Tokyo) 1999, 52:485-490.
95. Hu G.F., Riordan J.F., Vallee B.L. Aputative angiogenin receptor in angiogenin-responsive human endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:2204-2209.
96. Huang H., Hutta D.A., Hu H., DesJarlais R.L., Schubert C., Petrounia I.P., Chaikin M.A., Manthey C.L., Player M.R. Design and synthesis of a pyrido[2,3-d]pyrimidin-5-one class of anti-inflammatory FMS inhibitors. Bioorg. Med. Chem. Lett. 2008, 18:2355-2361.
97. Huang S., Mills L., Mian B., Tellez C., McCarty M., Yang X.D., Gudas J.M., Bar-Eli M. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am. J. Pathol. 2002, 161:125-134.
98. Huang X., Shen J., Cui M., Shen L., Luo X., Ling K., Pei G., Jiang H., Chen K. Molecular dynamics simulations on SDF-1a: binding with CXCR4 receptor. Biophys. J. 2003, 84:171-184.
99. Ikuta T., Ariga H., Matsumoto K. Extracellular matrix tenascin-X in combination with vascular endothelial growth factor B enhances endothelial cell proliferation. Genes Cells 2000, 5:913-927.
100. Iimuro S., Shindo T., Moriyama N., Amaki T., Niu P., Takeda N., Iwata H., Zhang Y., Ebihara A., Nagai R. Angiogenic effects of adrenomedullin in ischemia and tumor growth. Circ. Res. 2004, 95:415-423.
101. Inoue K., Slaton J.W., Eve B.Y., Kim S.J., Perrotte P., Balbay M.D., Yano S., Bar-Eli M., Radinsky R., Pettaway C.A., Dinney C.P. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin. Cancer Res. 2000, 6:2104-2119.
102. Jabbour E., Cortes J., Giles F., O'Brien S., Kantarijan H. Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond. IDrugs 2007, 10:468-479.
103. Jansson M., Uhlen M., Nilsson B. Structural changes in insulin-like growth factor IGF I mutant proteins affecting binding kinetic rates to IGF binding protein 1 and IGF-I receptor. Biochemistry 1997, 36:4108-4117.
104. Jarvis A., Allerston C.K., Jia H., Herzog B., Garza-Garcia A., Winfield N., Ellard K., Aqil R., Lynch R., Chapman C., Hartzoulakis B., Nally J., Stewart M., Cheng L., Menon M., Tickner M., Djordjevic S., Driscoll P.C., Zachary I., Selwood D.L. Small molecule inhibitors of the Neuropilin-1 vascular endothelial growth factor a (VEGF-A) interaction. J.Med. Chem. 2010, 53:2215-2226.
105. Jaye M., Schlessinger J., Dionne C.A. Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochim. Biophys. Acta 1992, 1135:185-199.
106. Jeon S.H., Chae B.C., Kim H.A., Seo G.Y., Seo D.W., Chun G.T., Kim N.S., Yie S.W., Byeon W.H., Eom S.H., Ha K.S., Kim Y.M., Kim P.H. Mechanisms underlying TGF-beta1-induced expression of VEGF and Flk-1 in mouse macrophages and their implications for angiogenesis. J.Leukoc. Biol. 2007, 81:557-566.
107. Jiang B.H., Zheng J.Z., Leung S.W., Roe R., Semenza G.L. Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J.Biol. Chem. 1997, 272:19253-19260.
108. Johnson D.E., Williams L.T. Structural and functional diversity in the FGF receptor multigene family. Adv. Cancer Res. 1993, 60:1-41.
109. Johnson L.N., Noble M.E.M., Owen D.J. Active and inactive protein kinases: structural basis for regulation. Cell 1996, 85:149-158.
110. Joukov V., Pajusola K., Kaipainen A., Chilov D., Lahtinen I., Kukk E., Saksela O., Kalkkinen N., Alitalo K. Anovel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996, 15:290-298.
111. Kaur G., Roy I. Therapeutic applications of aptamers. Expert Opin. Investig. Drugs 2008, 17:43-60.
112. Kawai J., Ando K., Tojo A., Shimosawa T., Takahashi K., Onozato M.L., Yamasaki M., Ogita T., Nakaoka T., Fujita T. Endogenous adrenomedullin protects against vascular response to injury in mice. Circulation 2004, 109:1147-1153.
113. Keefe D.M., Sonis S.T., Bowen J.M. Emerging drugs for chemotherapy-induced mucositis. Expert Opin. Emerg. Drugs 2008, 3:511-522.
114. Khandwala H.M., McCutcheon I.E., Flyvbjerg A., Friend K.E. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr. Rev. 2000, 21:215-244.
115. Kim J.H., Saito K., Yokoyama S. Chimeric receptor analyses of the interactions of the ectodomains of ErbB-1 with epidermal growth factor and of those of ErbB-4 with neuregulin. Eur. J. Biochem. 2002, 269:2323-2329.
116. Kim W., Moon S.O., Sung M.J., Kim S.H., Lee S., So J.N., Park S.K. Angiogenic role of adrenomedullin through activation of Akt, mitogenactivated protein kinase, and focal adhesion kinase in endothelial cells. FASEB. J. 2003, 17:1937-1939.
117. Kitamura K., Kangawa K., Kawamoto M., Ichiki Y., Nakamura S., Matsuo H., Eto T. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem. Biophys. Res. Commun. 1993, 192:553-560.
118. Klauber-DeMore N. Are epsins a therapeutic target for tumor angiogenesis?. J.Clin. Invest. 2012, 122(12):4341-4343.
119. Koch A.E., Polverini P.J., Kunkel S.L., Harlow L.A., DiPietro L.A., Elner V.M., Elner S.G., Strieter R.M. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992, 258:1798-1801.
120. Koh M.Y., Spivak-Kroizman T., Venturini S., Welsh S., Williams R.R., Kirkpatrick D.L., Powis G. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol. Cancer Ther. 2008, 7:90-100.
121. Koide H., Muto Y., Kasai H., Kohri K., Hoshi K., Takahashi S., Tsukumo K., Sasaki T., Oka T., Miyake T., Fuwa T., Kohda D., Inagaki F., Miyazawa T., Yokoyama S. Asite directed mutagenesis study on the role of isoleucine-23 of human epidermal growth factor in the receptor binding. Biochim. Biophys. Acta 1992, 1120:257-261.
122. Koide H., Muto Y., Kasai H., Hoshi K., Takusari H., Kohri K., Takahashi S., Sasaki T., Tsukumo K., Miyake T. Recognition of an antiparallel beta-sheet structure of human epidermal growth factor by its receptor. Site-directed mutagenesis studies of Ala-30 and Asn-32. FEBS. Lett. 1992, 302:39-42.
123. Komada M., Hatsuzawa K., Shibamoto S., Ito F., Nakayama K., Kitamura N. Proteolytic processing of the hepatocyte growth factor/scatter factor receptor by furin. FEBS. Lett. 1993, 328:25-29.
124. Kong B.M., Stamos J., Wickramasinghe D. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell. 2004, 6:75-84.
125. Kuenen B.C., Giaccone G., Ruijter R., Kok A., Schalkwijk C., Hoekman K., Pinedo H.M. Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies. Clin. Cancer Res. 2005, 11:6240-6246.
126. Kung A.L., Wang S., Klco J.M., Kaelin W.G., Livingston D.M. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat. Med. 2000, 6:1335-1340.
127. Lando D., Peet D.J., Gorman J.J., Whelan D.A., Whitelaw M.L., Bruick R.K. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes. Dev. 2002, 16:1466-1471.
128. LaRochelle W.J., Giese N., May-Siroff M., Robbins K.C., Aaronson S.A. Molecular localization of the transforming and secretory properties of PDGF A and PDGF B. Science 1990, 248:1541-1544.
129. Laschke M.W., Elitzsch A., Vollmer B., Vajkoczy P., Menger M.D. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppress angiogenesis and vessel maturation in endometriotic lesions. Hum. Reprod. 2006, 21:262-268.
130. Lee C.C., Kreusch A., McMullan D., Ng K., Spraggon G. Crystal structure of the human Neuropilin-1 b1 domain. Structure 2003, 11:99-108.
131. Lee J., Blaber M. The interaction between thermodynamic stability and buried free cysteines in regulating the functional half-life of fibroblast growth factor-1. J.Mol. Biol. 2009, 393:113-127.
132. Lemmon M.A., Schlessinger J. Regulation of signal transduction and signal diversity by receptor oligomerization. Trends. Biochem. Sci. 1994, 19:459-463.
133. Leonidas D.D., Shapiro R., Allen S.C., Subbarao G.V., Veluraja K., Acharya K.R. Refined crystal structures of native human angiogenin and two active site variants: implications for the unique functional properties of an enzyme involved in neovascularisation during tumour growth. J.Mol. Biol. 1999, 285:1209-1233.
134. Leonidas D.D., Shapiro R., Subbarao G.V., Russo A., Acharya K.R. Crystallographic studies on the role of the C-terminal segment of human angiogenin in defining enzymatic potency. Biochemistry 2002, 41:2552-2562.
135. Leppänen V.M., Jeltsch M., Anisimov A., Tvorogov D., Aho K., Kalkkinen N., Toivanen P., Ylä-Herttuala S., Ballmer-Hofer K., Alitalo K. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity. Blood 2011, 117:1507-1515.
136. Leppänen V.M., Prota A.E., Jeltsch M., Anisimov A., Kalkkinen N., Strandin T., Lankinen H., Goldman A., Ballmer-Hofer K., Alitalo K. Structural determinants of growth factor binding and specificity by VEGF receptor 2. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:2425-2430.
137. Li A., Dubey S., Varney M.L., Dave B.J., Singh R.K. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J.Immunol. 2003, 170:3369-3376.
138. Li B., Vincent A., Cates J., Brantley-Sieders D.M., Polk D.B., Young P.P. Low levels of tumor necrosis factor a increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. Cancer Res. 2009, 69:338-348.
139. Li Y., Zhang F., Nagai N., Tang Z., Zhang S., Scotney P., Lennartsson J., Zhu C., Qu Y., Fang C., Hua J., Matsuo O., Fong G.H., Ding H., Cao Y., Becker K.G., Nash A., Heldin C.H., Li X. VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats. J.Clin. Invest. 2008, 118:913-923.
140. Li Z., Xu M., Xing S., Ho W.T., Ishii T., Li Q., Fu X., Zhao Z.J. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J.Biol. Chem. 2007, 282:3428-3432.
141. Lietha D., Chirgadze D.Y., Mulloy B., Blundell T.L., Gherardi E. Crystal structures of NK1-heparin complexes reveal the basis of NK1 activity and enable engineering of potent agonists of the MET receptor. EMBO J. 2001, 20:5543-5555.
142. Linnell J., Groeger G., Hassan A.B. Real, time kinetics of insulin like growth factor II (IGF-II) interaction with the IGF-II/mannose 6-phosphate receptor: the effects of domain 13 and pH. J.Biol. Chem. 2001, 276:23986-23991.
143. Loeffler S., Fayard B., Weis J., Weissenberger J. Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes invivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1. Int. J. Cancer 2005, 115:202-213.
144. Lokker N.A., Mark M.R., Luis E.A., Bennett G.L., Robbins K.A., Baker J.B., Godowski P.J. Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J. 1992, 11:2503-2510.
145. Lowman H.B., Fairbrother W.J., Slagle P.H., Kabakoff R., Liu J., Shire S., Hébert C.A. Monomeric variants of IL-8: effects of sidechain substitutions and solution conditions upon dimer formation. Protein Sci. 1997, 6:598-608.
146. Lozano R.M., Jiménez M., Santoro J., Rico M., Giménez-Gallego G. Solution structure of acidic fibroblast growth factor bound to 1,3, 6-naphthalenetrisulfonate: a minimal model for the anti-tumoral action of suramins and suradistas. J.Mol. Biol. 1998, 281:899-915.
147. Lu C., Mi L.Z., Grey M.J., Zhu J., Graef E., Yokoyama S., Timothy A. Structural evidence for loose linkage between ligand binding and kinase activation in the epidermal growth factor receptor. Mol. Cell Biol. 2010, 30:5432-5443.
148. Lu H.S., Chai J.J., Li M., Huang B.R., He C.H., Bi R.C. Crystal structure of human epidermal growth factor and its dimerization. J.Biol. Chem. 2001, 276:34913-34917.
149. Lucyk S., Taha H., Yamamoto H., Miskolzie M., Kotovych G. NMR conformational analysis of proadrenomedullin N-terminal 20 peptide, a proangiogenic factor involved in tumor growth. Biopolymers 2006, 81:295-308.
150. Luke R.W., Ballard P., Buttar D., Campbell L., Curwen J., Emery S.C., Griffen A.M., Hassall L., Hayter B.R., Jones C.D., McCoull W., Mellor M., Swain M.L., Tucker J.A. Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with activity against Tie-2 invitro and invivo. Bioorg. Med. Chem. Lett. 2009, 19:6670-6674.
151. Luker K.E., Luker G.D. Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett. 2006, 238:30-41.
152. Lyon M., Deakin J.A., Lietha D., Gherardi E., Gallagher J.T. The interactions of hepatocyte growth factor/scatter factor and its NK1 and NK2 variants with glycosaminoglycans using a modified gel mobility shift assay. J.Biol. Chem. 2004, 42:43560-43567.
153. Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziejewski C., Compton D.L., McClain J., Aldrich T.H., Papadopoulos N., Daly T.J., Davis S., Sato T.N., Yancopoulos G.D. Angiopoietin-2, a natural antagonist for Tie2 that disrupts invivo angiogenesis. Science 1997, 277:55-60.
154. Makinen T., Olofsson B., Karpanen T., Hellman U., Soker S., Klagsbrun M., Eriksson U., Alitalo K. Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1. J.Biol. Chem. 1999, 274:21217-21222.
155. Malik R., Roy I. Design and development of antisense drugs. Expert Opin. Drug Discov. 2008, 3:1189-1207.
156. Mamluk R., Gechtman Z., Kutcher M.E., Gasiunas N., Gallagher J., Klagsbrun M. Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain. J.Biol. Chem. 2002, 277:24818-24825.
157. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
158. 2-terminal 20 peptide is a potent angiogenic factor, and its inhibition results in reduction of tumor growth. Cancer Res. 2004, 64:6489-6494.
159. Massague J. Epidermal growth factor-like transforming growth factor 11. Interaction with epidermal growth factor receptors in human placenta membranes and A431 cells. J.Biol. Chem. 1983, 258:13614-13620.
160. Matter A. Tumor angiogenesis as a therapeutic target. Drug Discov. Today 2001, 6:1005-1024.
161. McIntosh I., Bellus G.A., Jab E.W. The pleiotropic effects of fibroblast growth factor receptors in mammalian development. Cell. Struct. Funct. 2000, 25:85-96.
162. McLatchie L.M., Fraser N.J., Main M.J., Wise A., Brown J., Thompson N., Solari R., Lee M.G., Foord S.M. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998, 393:333-339.
163. Mohan S.K., Rani S.G., Yu C. The heterohexameric complex structure, a component in the non-classical pathway for fibroblast growth factor 1 (FGF1) secretion. J.Biol. Chem. 2010, 285:15464-15475.
164. Moroianu J., Riordan J.F. Identification of the nucleolar targeting signal of human angiogenin. Biochem. Biophys. Res. Commun. 1994, 203:1765-1772.
165. Moroianu J., Riordan J.F. Nuclear translocation of angiogenin in proliferating endothelial cells is essential to its angiogenic activity. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:1677-1681.
166. Muller Y.A., Chen Y., Christinger H.W., Li B., Cunningham B.C., Lowman H.B., de Vos A.M. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Structure 1998, 6:1153-1167.
167. Murdoch C., Monk P.N., Finn A. CXC chemokine receptor expression on human endothelial cells. Cytokine 1999, 11:704-712.
168. Murphy J.W., Yuan H., Kong Y., Xiong Y., Lolis E.J. Heterologous quaternary structure of CXCL12 and its relationship to the CC chemokine family. Proteins 2010, 78:1331-1337.
169. Nakao-Hayashi J., Ito H., Kanayasu T., Morita I., Murota S. Stimulatory effects of insulin and insulin-like growth factor I on migration and tube formation by vascular endothelial cells. Atherosclerosis 1992, 92:141-149.
170. Naski M.C., Ornitz D.M. FGF signaling in skeletal development. Front. Biosci. 1998, 3:D781-D794.
171. Nelson M.H., Dolder C.R. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann. Pharmacother. 2006, 40:261-269.
172. Nikitenko L.L., Fox S.B., Kehoe S., Rees M.C.P., Bicknell R. Adrenomedullin and tumour angiogenesis. Br. J. Cancer 2006, 94:1-7.
173. Nikitenko L.L., MacKenzie I.Z., Rees M.C.P., Bicknell R. Adrenomedullin is an autocrine regulator of endothelial growth in human endometrium. Mol. Hum. Reprod. 2000, 6:811-819.
174. Nikitenko L.L., Smith D.M., Bicknell R., Rees M.C.P. Transcriptional regulation of the CRLR gene in human microvascular endothelial cells by hypoxia. FASEB. J. 2003, 17:1499-1501.
175. Oehler M.K., Hague S., Rees M.C., Bicknell R. Adrenomedullin promotes formation of xenografted endometrial tumors by stimulation of autocrine growth and angiogenesis. Oncogene 2002, 21:2815-2821.
176. Ogiso H., Ishitani R., Nureki O., Fukai S., Yamanaka M., Kim J., Saito K., Sakamoto A., Inoue M., Shirouzu M., Yokoyama S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002, 110:775-787.
177. Olson K.A., Byers H.R., Key M.E., Fett J.W. Inhibition of prostate carcinoma establishment and metastatic growth in mice by an antiangiogenin monoclonal antibody. Int. J. Cancer 2002, 98:923-929.
178. Olson K.A., Fett J.W., French T.C., Key M.E., Vallee B.L. Angiogenin antagonists prevent tumor growth invivo. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:442-446.
179. Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., Carey V.J., Richardson A.L., Weinberg R.A. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348.
180. Orlova A., Magnusson M., Eriksson T.L., Nilsson M., Larsson B., Höidén-Guthenberg I., Widström C., Carlsson J., Tolmachev V., Ståhl S., Nilsson F.Y. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 2006, 66:4339-4348.
181. Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A., Coulier F., Gao G., Goldfarb M. Receptor specificity of the fibroblast growth factor family. J.Biol. Chem. 1996, 271:15292-15297.
182. Otsuka T., Jakubczak J., Vieira W., Bottaro D.P., Breckenridge D., Larochelle W.J., Merlino G. Disassociation of met-mediated biological responses invivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis. Mol. Cell Biol. 2000, 20:2055-2065.
183. Overington J.P., Al-Lazikani B., Hopkins A.L. How many drug targets are there?. Nat. Rev. Drug Discov. 2006, 5:993-996.
184. Pakianathan D., Kuta E., Skelton N.J., Artis D.R., Hébert C.A. Distinct but overlapping epitopes for the interaction of RANTES with CCR1, CCR3 and CCR5. Biochemistry 1997, 36:9642-9648.
185. Park J.E., Chen H.H., Winer J., Houck K.A., Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, invitro and invivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J.Biol. Chem. 1994, 269:25646-25654.
186. Pavlov N., Badet J. Angiogenin: involvement in angiogenesis and tumour growth. Bull Cancer 2001, 88:725-732.
187. Peifer C., Stoiber T., Unger E., Totzke F., Schächtele C., Marmé D., Brenk R., Klebe G., Schollmeyer D., Dannhardt G. Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J.Med. Chem. 2006, 49:1271-1281.
188. Pérez-Castells J., Martín-Santamaría S., Nieto L., Ramos A., Martínez A., Pascual-Teresa B., Jiménez-Barbero J. Structure of micelle-bound adrenomedullin: a first step toward the analysis of its interactions with receptors and small molecules. Biopolymers 2012, 97:45-53.
189. Pineda-Lucena A., Jiménez M.A., Lozano R.M., Nieto J.L., Santoro J., Rico M., Giménez-Gallego G. Three-dimensional structure of acidic fibroblast growth factor in solution: effects of binding to a heparin functional analog. J.Mol. Biol. 1996, 264:162-178.
190. Podar K., Tai Y.T., Hideshima T., Vallet S., Richardson P.G., Anderson K.C. Emerging therapies for multiple myeloma. Expert Opin. Emerg. Drugs 2009, 14:99-127.
191. Poyner D.R., Sexton P.M., Marshall I., Smith D.M., Quirion R., Born W., Muff R., Fischer J.A., Foord S.M. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol. Rev. 2002, 54:233-246.
192. Pugh C.W., O'Rourke J.F., Nagao M., Gleadle J.M., Ratcliffe P.J. Activation of hypoxia-inducible factor-1, definition of regulatory domains within the alpha subunit. J.Biol. Chem. 1997, 272:11205-11214.
193. Rabinovsky E. The multifunctional role of IGF-1 in peripheral nerve regeneration. Neurol. Res. 2004, 26:204-210.
194. Reigstad L.J., Sande H.M., Fluge Ø., Bruland O., Muga A., Varhaug J.E., Martinez A., Lillehaug J.R. Platelet-derived growth factor (PDGF)-C, a PDGF family member with a vascular endothelial growth factor-like structure. J.Biol. Chem. 2003, 278:17114-17120.
195. Rey S., Semenza G.L. Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. Cardiovasc. Res. 2010, 86:236-242.
196. Ribatti D., Nico B., Ranieri G., Specchia G., Vacca A. The role of angiogenesis in human non-Hodgkin lymphomas. Neoplasia 2013, 15(3):231-238.
197. Ribatti D., Guidolin D., Conconi M.T., Nico B., Baiguera S., Parnigotto P.P., Vacca A., Nussdorfer G.G. Vinblastine inhibits the angiogenic response induced by adrenomedullin invitro and invivo. Oncogene 2003, 22:6458-6461.
198. Richter A., Drummond D.R., MacGarvie J., Puddicombe S.M., Chamberlin S.G., Davies D.E. Contribution of the transforming growth factor alpha B-loop beta-sheet to binding and activation of the epidermal growth factor receptor. J.Biol. Chem. 1995, 270:1612-1616.
199. Roskoski R. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit. Rev. Oncol. Hematol. 2007, 62:179-213.
200. Ross R., Raines E.W., Bowen-Pope D.F. The biology of platelet-derived growth factor. Cell 1986, 46:155-169.
201. Roy Choudhury S., Karmakar S., Banik N.L., Ray S.K. Targeting angiogenesis for controlling neuroblastoma. J.Oncol. 2012, 2012:782020.
202. Ruggeri B.A., Robinson C., Angeles T., Wilkinson J., Clapper M.L. The chemopreventive agent oltipraz possesses potent antiangiogenic activity invitro, exvivo, and invivo and inhibits tumor xenograft growth. Clin. Cancer Res. 2002, 8:267-274.
203. Ryu E.K., Kim T.G., Kwon T.H. Crystal structure of recombinant human stromal cell-derived factor-1a. Proteins 2007, 67:1193-1197.
204. Sablone M.R., Cesta M.C., Moriconi A., Aramini A., Bizzarri C., Di Giacinto C., Di Bitondo R., Gloaguen I., Aschi M., Crucianelli M., Bertini R., Allegretti M. Structure-activity relationship of novel phenylacetic CXCR1 inhibitors. Bioorg. Med. Chem. Lett. 2009, 19:4026-4030.
205. Sadir R., Imberty A., Baleux F., Lortat-Jacob H. Heparan sulfate/heparin oligosaccharides protect stromal cell-derived factor-1 (SDF-1)/CXCL12 against proteolysis induced by CD26/dipeptidyl peptidase IV. J.Biol. Chem. 2004, 279:43854-43860.
206. Saijo Y., Tanaka M., Miki M., Usui K., Suzuki T., Maemondo M., Hong X., Tazawa R., Kikuchi T., Matsushima K., Nukiwa T. Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: invivo analysis of tumor-stromal interaction. J.Immunol. 2002, 169:469-475.
207. Santoro J., Gonzalez C., Bruix M., Neira J.L., Nieto J.L., Herranz J., Rico M. High-resolution three-dimensional structure of ribonuclease A in solution by nuclear magnetic resonance spectroscopy. J.Mol. Biol. 1993, 229:722-734.
208. Sarker D., Molife R., Evans T.R., Hardie M., Marriott C., Butzberger-Zimmerli P., Morrison R., Fox J.A., Heise C., Louie S., Aziz N., Garzon F., Michelson G., Judson I.R., Jadayel D., Braendle E., de Bono J.S. Aphase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin. Cancer Res. 2008, 14:2075-2081.
209. Sato Y., Okamura K., Morimoto A., Hamanaka R., Hamaguchi K., Shimada T., Ono M., Kohno K., Sakata T., Kuwano M. Indispensable role of tissue-type plasminogen activator in growth factor-dependent tube formation of human microvascular endothelial cells invitro. Exp. Cell. Res. 1993, 204:223-229.
210. Schlessinger J., Lax I., Lemmon M. Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors?. Cell 1995, 83:357-360.
211. Schlessinger J., Plotnikov A.N., Ibrahimi O.A., Eliseenkova A.V., Yeh B.K., Yayon A., Linhardt R.J., Mohammadi M. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol. Cell 2000, 6:743-750.
212. Seghezzi G., Patel S., Ren C.J., Gualandris A., Pintucci G., Robbins E.S., Shapiro R.L., Galloway A.C., Rifkin D.B., Mignatti P. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J.Cell. Biol. 1998, 141:1659-1673.
213. Semenza G.L. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010, 29:625-634.
214. Shapiro R., Riordan J.F., Vallee B.L. Characteristic ribonucleolytic activity of human angiogenin. Biochemistry 1986, 25:3527-3532.
215. Shapiro R., Strydom D.J., Olson K.A., Vallee B.L. Isolation of angiogenin from normal human plasma. Biochemistry 1987, 26:5141-5146.
216. Shapiro R., Vallee B.L. Site-directed mutagenesis of histidine-13 and histidine-1 14 of human angiogenin. Alanine derivatives inhibit angiogenin-induced angiogenesis. Biochemistry 1989, 28:7401-7408.
217. Shima A.H., Liua H., Fociaa P.J., Chena X., Linb P.C., Hea X. Structures of a platelet-derived growth factor/propeptide complex and a platelet-derived growth factor/receptor complex. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:11307-11312.
218. Shindo T., Kurihara Y., Nishimatsu H., Moriyama N., Kakoki M., Wang Y., Imai Y., Ebihara A., Kuwaki T., Ju K.H., Minamino N., Kangawa K., Ishikawa T., Fukuda M., Akimoto Y., Kawakami H., Imai T., Morita H., Yazaki Y., Nagai R., Hirata Y., Kurihara H. Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin gene. Circulation 2001, 104:1964-1971.
219. Siwanowicz I., Popowicz G.M., Wisniewska M., Huber R., Kuenkele K.P., Lang K., Engh R.A., Holak T.A. Structural basis for the regulation of insulin-like growth factors by IGF binding proteins. Structure 2005, 13:155-167.
220. So A., De Smedt T., Revaz S., Tschopp J. Apilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 2007, 9:R28.
221. Soker S., Takashima S., Miao H.Q., Neufeld G., Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998, 92:735-745.
222. Soncin F. Angiogenin supports endothelial and fibroblast cell adhesion. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:2232-2236.
223. Spivak-Kroizman T., Lemmon M.A., Dikic I., Ladbury J.E., Pinchasi D., Huang J., Jaye M., Crumley G., Schlessinger J., Lax I. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell 1994, 79:1015-1024.
224. Stacker S.A., Stenvers K., Caesar C., Vitali A., Domagala T., Nice E., Roufail S., Simpson R.J., Moritz R., Karpanen T., Alitalo K., Achen M.G. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J.Biol. Chem. 1999, 274:32127-32136.
225. Starovasnik M.A., Braisted A.C., Wells J.A. Structural mimicry of a native protein by a minimized binding domain. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:10080-10085.
226. Tadaki D.K., Niyogi S.K. The functional importance of hydrophobicity of the tyrosine at position 13 of human epidermal growth factor in receptor binding. J.Biol. Chem. 1993, 268:10114-10119.
227. Tamatani T., Hattori K., Iyer A., Tamatani K., Oyasu R. Hepatocyte growth factor is an invasion/migration factor of rat urothelial carcinoma cells invitro. Carcinogenesis 1999, 20:957-962.
228. Tammela T., Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell 2010, 140:460-476.
229. Tammela T., Zarkada G., Wallgard E., Murtomäki A., Suchting S., Wirzenius M., Waltari M., Hellström M., Schomber T., Peltonen R., Freitas C., Duarte A., Isoniemi H., Laakkonen P., Christofori G., Ylä-Herttuala S., Shibuya M., Pytowski B., Eichmann A., Betsholtz C., Alitalo K. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008, 454:656-660.
230. Taylor A.P., Rodriguez M., Adams K., Goldenberg D.M., Blumenthal R.D. Altered tumor vessel maturation and proliferation in placenta growth factor-producing tumors: potential relationship to post-therapy tumor angiogenesis and recurrence. Int. J. Cancer 2003, 105:158-164.
231. Testa U., Riccioni R., Diverio D., Rossini A., Lo Coco F., Peschle C. Interleukin-3 receptor in acute leukemia. Leukemia 2004, 18:219-226.
232. Thevis M., Kohler M., Schlörer N., Schänzer W. Gas phase reaction of substituted isoquinolines to carboxylic acids in ion trap and triple quadrupole mass spectrometers after electrospray ionization and collision-induced dissociation. J.Am. Soc. Mass. Spectrom. 2008, 19:151-158.
233. Tolberta W.D., Holtropa J.D., Gherardib E., Woudec G.V., Xua H.E. Structural basis for agonism and antagonism of hepatocyte growth factor. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:13264-13269.
234. Tschesche H., Kopp C., Horl W.H., Hempelmann U. Inhibition of degranulation of polymorphonuclear leukocytes by angiogenin and its tryptic fragment. J.Biol. Chem. 1994, 269:30274-30280.
235. Tzahar E., Waterman H., Chen X., Levkowitz G., Karunagaran D., Lavi S., Ratzkin B.J., Yarden Y.A. Ahierarchical network of interreceptor interactions determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell Biol. 1996, 16:5276-5287.
236. Van de Poll M.L., Van Vugt M.J., Lenferink A.E., Van Zoelen E.J. Insertion of Argos sequences into the B-loop of epidermal growth factor results in a low-affinity ligand with strong agonistic activity. Biochemistry 1997, 36:7425-7431.
237. Van Zoelen E.J.J., Stortelers C., Lenferink A.E.G., Van De Poll M.L.M. The EGF domain: requirements for binding to receptors of the ErbB family. Vitam. Horm. 2000, 59:99-131.
238. Vander Kooi C.W., Jusino M.A., Perman B., Neau D.B., Bellamy H.D., Leahy D.J. Structural basis for ligand and heparin binding to neuropilin B domains. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:6152-6157.
239. Veerapandian B., Gilliland G.L., Raag R., Svensson A.L., Masui Y., Hirai Y., Poulos T.L. Functional implications of interleukin-1 beta based on the three-dimensional structure. Proteins 1992, 12:10-23.
240. Veikkola T., Alitalo K. VEGFs, receptors and angiogenesis. Semin. Cancer Biol. 1999, 9:211-220.
241. Veldkamp C.T., Seibert C., Peterson F.C., Sakmar T.P., Volkman B.F. Recognition of a CXCR4 sulfotyrosine by the chemokine stromal cell-derived factor-1[alpha] (SDF-1[alpha]/CXCL12). J.Mol. Biol. 2006, 359:1400-1409.
242. Vigers G.P., Anderson L.J., Caffes P., Brandhuber B.J. Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1beta. Nature 1997, 386:190-194.
243. 2 tension. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:5510-5514.
244. Ward C.W., Hoyne P.A., Flegg R.H. Insulin and epidermal growth factor receptors contain the cysteine repeat motif found in the tumor necrosis factor receptor. Proteins 1995, 22:141-153.
245. Wei L.H., Kuo M.L., Chen C.A., Chou C.H., Lai K.B., Lee C.N., Hsieh C.Y. Interleukin-6 promotes cervical tumor growth by VEGF dependent angiogenesis via a STAT3 pathway. Oncogene 2003, 22:1517-1527.
246. Wetterau L.A., Moore M.G., Lee K.W., Shim M.L., Cohen P. Novel aspects of the insulin-like growth factor binding proteins. Mol. Genet. Metab. 1999, 68:161-181.
247. Wilkinson I.C., Hall C.J., Veverka V., Shi J.Y., Muskett F.W., Stephens P.E., Taylor R.J., Henry A.J., Carr M.D. High resolution NMR-based model for the structure of a scFv-IL-1beta complex potential for NMR as a key tool in therapeutic antibody design and development. J.Biol. Chem. 2009, 284:31928-31935.
248. Williams G., Borkakoti N., Bottomley G.A., Cowan I., Fallowfield A.G., Jones P.S., Kirtland S.J., Price G.J., Price L. Mutagenesis studies of IL-8. Identification of a second epitope involved in receptor binding. J.Biol. Chem. 1996, 271:9579-9586.
249. Wingens M., Walma T., van Ingen H., Stortelers C., van Leeuwen J.E., van Zoelen E.J., Vuister G.W. Structural analysis of an epidermal growth factor/transforming growth factor-alpha chimera with unique ErbB binding specificity. J.Biol. Chem. 2003, 278:39114-39123.
250. Witzenbichler B., Maisonpierre P.C., Jones P., Yancopoulos G.D., Isner J.M. Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2. J.Biol. Chem. 1998, 273:18514-18521.
251. Wlodawer A., Svensson L.A., Sjolin L., Gilliland G.L. Structure of phosphate-free ribonuclease A refined at 1.26 A. Biochemistry 1988, 27:2705-2717.
252. Woolard J., Wang W.Y., Bevan H.S., Qiu Y., Morbidelli L., Pritchard-Jones R.O., Cui T.G., Sugiono M., Waine E., Perrin R., Foster R., Digby-Bell J., Shields J.D., Whittles C.E., Mushens R.E., Gillatt D.A., Ziche M., Harper S.J., Bates D.O. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, invivo effect on angiogenesis and endogenous protein expression. Cancer Res. 2004, 64:7822-7835.
253. Wu M., Rivkin A., Pham T. Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer. Clin. Ther. 2008, 30:14-30.
254. Zeoli A., Dentelli P., Rosso A., Togliatto G., Trombetta A., Damiano L., di Celle P.F., Pegoraro L., Altruda F., Brizzi M.F. Interleukin-3 promotes expansion of hemopoietic-derived CD45+ angiogenic cells and their arterial commitment via STAT5 activation. Blood 2008, 112:350-361.
255. Zeslawski W., Beisel H.G., Kamionka M., Kalus W., Engh R.A., Huber R., Lang K., Holak T.A. The interaction of insulin-like growth factor-I with the N-terminal domain of IGFBP-5. EMBO J. 2001, 20:3638-3644.
256. Zhang F., Tang Z., Hou X., Lennartsson J., Li Y., Koch A.W., Scotney P., Lee C., Arjunan P., Dong L., Kumar A., Rissanen T.T., Wang B., Nagai N., Fons P., Fariss R., Zhang Y., Wawrousek E., Tansey G., Raber J., Fong G.H., Ding H., Greenberg D.A., Becker K.G., Herbert J.M., Nash A., Yla-Herttuala S., Cao Y., Watts R.J., Li X. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:6152-6157.
257. Zhao Y., Hague S., Manek S., Zhang L., Bicknell R., Rees M.C.P. PCR display identifies tamoxifen induction of the novel angiogenic factor adrenomedullin by a non estrogenic mechanism in the human endometrium. Oncogene 1998, 16:409-415.
258. Zhu F., Shi Z., Qin C., Tao L., Liu X., Xu F., Zhang L., Song Y., Liu X., Zhang J., Han B., Zhang P., Chen Y. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012, 40:D1128-D1136.
259. Zimmermann J., Buchdunger E., Mett H., Meyer T., Lydon N.B. Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives. Bioorg. Med. Chem. Lett. 1997, 7:187-192.
260. Zimmermann J., Caravatti G., Mett H., Meyer T., Müller M., Lydon N.B., Fabbro D. Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors. Med. Chem. Let 1996, 6:1221-1226.
261. Zudaire E., Martinez A., Cuttitta F. Adrenomedullin and cancer. Regul. Pept. 2003, 112:175-183.